Literature DB >> 24917080

Efficacy and safety of fractional carbon dioxide laser for treatment of unwanted facial freckles in phototypes II-IV: a pilot study.

Bakr El Zawahry1, Naglaa Zaki, Vanessa Hafez, Rania Abdel Hay, Rania Abdel Hay, Aya Fahim.   

Abstract

Facial freckles are a cosmetic concern to Egyptians, particularly young females. Several therapeutic lines exist with variable response rates and limitations. Fractional carbon dioxide (FCO2) laser provides minimal ablation and therefore less down time and less side effects. The efficacy and safety of this laser technology have still not been studied in freckles. The aim of this study is to assess the efficacy and safety of FCO2 laser in the treatment of unwanted facial freckles in Egyptians. Twenty patients undergone a single session of FCO2 laser and then were followed up clinically a month later. Photographs were taken before treatment and at follow-up visit and were assessed by three blinded investigators. Percent of global improvement was measured on a 4-point grading scale. Patient's satisfaction and adverse events were recorded. Two patients (10 %) showed grade 1 improvement, while eight patients (40 %) showed grade 2 improvement. Nine patients (45 %) showed grade 3 improvement, and only one patient (5 %) showed grade 4 improvement. FCO2 laser resurfacing is effective and safe in treatment of facial freckles in skin phototypes II-IV. It can offer a more practical alternative to topical treatments, and a cheaper alternative to Q-switched lasers.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24917080     DOI: 10.1007/s10103-014-1610-8

Source DB:  PubMed          Journal:  Lasers Med Sci        ISSN: 0268-8921            Impact factor:   3.161


  22 in total

1.  Skin responses to fractional photothermolysis.

Authors:  Hans-Joachim Laubach; Zeina Tannous; R Rox Anderson; Dieter Manstein
Journal:  Lasers Surg Med       Date:  2006-02       Impact factor: 4.025

Review 2.  Lasers for scars: a review.

Authors:  Keyvan Nouri; Kelley Vidulich; Maria Patricia Rivas
Journal:  J Cosmet Dermatol       Date:  2006-03       Impact factor: 2.696

3.  The use of Q-switched Nd:YAG laser in the treatment of superficial pigmented lesions in Koreans.

Authors:  D H Suh; K H Han; J H Chung
Journal:  J Dermatolog Treat       Date:  2001-06       Impact factor: 3.359

Review 4.  Laser eradication of pigmented lesions: a review.

Authors:  Kristel D Polder; Jennifer M Landau; Irene J Vergilis-Kalner; Leonard H Goldberg; Paul M Friedman; Suzanne Bruce
Journal:  Dermatol Surg       Date:  2011-04-14       Impact factor: 3.398

5.  Laser therapy of freckles and lentigines with quasi-continuous, frequency-doubled, Nd:YAG (532 nm) laser in Fitzpatrick skin type IV: a 24-month follow-up.

Authors:  T Rashid; I Hussain; M Haider; T S Haroon
Journal:  J Cosmet Laser Ther       Date:  2002-12       Impact factor: 2.247

6.  The melanocortin-1-receptor gene is the major freckle gene.

Authors:  M Bastiaens; J ter Huurne; N Gruis; W Bergman; R Westendorp; B J Vermeer; J N Bouwes Bavinck
Journal:  Hum Mol Genet       Date:  2001-08-01       Impact factor: 6.150

7.  A comparison of Q-switched and long-pulsed alexandrite laser for the treatment of freckles and lentigines in oriental patients.

Authors:  S G Y Ho; C K Yeung; N P Y Chan; S Y Shek; H H L Chan
Journal:  Lasers Surg Med       Date:  2011-02       Impact factor: 4.025

8.  The treatment of melasma with topical creams alone, CO2 fractional ablative resurfacing alone, or a combination of the two: a comparative study.

Authors:  Mario A Trelles; Mariano Velez; Michael H Gold
Journal:  J Drugs Dermatol       Date:  2010-04       Impact factor: 2.114

Review 9.  Topical agents used in the management of hyperpigmentation.

Authors:  R M Halder; G M Richards
Journal:  Skin Therapy Lett       Date:  2004 Jun-Jul

10.  Combined use of intense pulsed light and Q-switched ruby laser for complex dyspigmentation among Asian patients.

Authors:  Jong Min Park; Hensin Tsao; Sandy Tsao
Journal:  Lasers Surg Med       Date:  2008-02       Impact factor: 4.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.